title: Diabetic neuropathies.
abstract: OBJECTIVE
  This article provides an overview for understanding the diagnosis, pathogenesis, and management of diabetic neuropathy.
  
  
  RESULTS
  New information about the pathogenesis of diabetic neuropathy continues to emerge, which will lead to identifying new drug targets. It is clear that the natural history of diabetic neuropathy is changing and the rate of progression is slowing. This is likely because of a combination of earlier diagnosis, improved glycemic management, and improved control of related complications such as hyperlipidemia and hypertension. Early diagnosis is critical, and small fiber neuropathy or subclinical diabetic neuropathy may be reversed or significantly improved with appropriate intervention. The American Academy of Neurology recently published guidelines for the treatment of painful diabetic neuropathy.
  
  
  CONCLUSIONS
  Diabetic neuropathy is common and can present with varied clinical presentations discussed in this article. Although treatment currently focuses on pain management, attention should be paid to potential risk factors for neuropathy. For example, glycemic control, hyperlipidemia, and hypertension should be managed with diet, exercise, and medications. Class I or II clinical studies indicate that pregabalin, duloxetine, amitriptyline, gabapentin, and opioids are effective in the management of diabetic neuropathic pain.
authors.forename: James W
authors.initials: JW
authors.lastname: Russell
authors.forename: Lindsay A
authors.initials: LA
authors.lastname: Zilliox
mesh_terms: D003929:Diabetic Neuropathies / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D006801:Humans